A recent meta-analysis has suggested a link between atopic dermatitis (AD) and delinquent behaviours in children and adolescents in the US.
New study shows Tapinarof cream reduces severity of plaque psoriasis
Tapinarof 1% cream was superior to vehicle control in reducing the severity of plaque psoriasis over a 12 week period, according to a new study.
Study shows higher doses of upadacitinib produce added benefit in moderate-to-severe AD
Higher doses of upadicitinib show added benefits for adults with moderate-to-severe atopic dermatitis (AD) when compared to dupilumab, according to a new study.
New study finds AD patients may be at greater risk of systemic and psychiatric comorbidities
According to a new study, adults with atopic dermatitis (AD) have a higher incidence of systemic, autoimmune, and psychiatric comorbidities than those without AD.
New study shows AD patients on dupilumab may experience less severe Covid-19 symptoms
Patients being treated with dupilumab for atopic dermatitis (AD) may experience less severe Covid-19 symptoms, according to a new study.
Pre-pregnancy obesity may be linked to increased risk of AD in infants, study finds
New research has suggested that intrauterine mechanisms of overweight women in pre-pregnancy may have increased risks of their infants having atopic dermatitis (AD).
New study links key protein to inflammation in psoriasis patients
Researchers have linked a key protein called TWEAK to inflammation in psoriasis patients.
Risankizumab worsened symptoms in patients with severe asthma, new study finds
A new study tested risankizumab, approved for the treatment of psoriasis, in patients with severe asthma and found it worsened their asthma symptoms.
Researchers gather real world treatment data on psoriatic arthritis patients
Researchers have surveyed 137 respondents from a psoriatic arthritis (PsA) registry for phenotypic features and characteristics, initial and current therapies, and medication preference.
Dupilumab linked to reduced itch in prurigo nodularis patients, according to study
Results of a phase 3 trial have linked dupilumab to significantly reduced skin lesions and itch when compared to placebo in adult prurigo nodularis patients, according to a press release (Oct. 22, 2021).
HealthMinute.TV 